

Clearbridge Enters into Agreement to Purchase Sinopharm COVID-19 Vaccine for Use in Singapore

- *Clearbridge to procure the Sinopharm COVID-19 Vaccine directly from the manufacturer*
- *The Group's subsidiary, Medic Surgical, has obtained the relevant approvals to import and supply the Sinopharm COVID-19 Vaccine in Singapore*
- *The Group is currently exploring opportunities in other markets for the Sinopharm COVID-19 Vaccine*

SINGAPORE, 9 August 2021 – Asia's integrated healthcare company, **Clearbridge Health Limited** ("Clearbridge" or the "Company" and, together with its subsidiaries, the "Group") ("明策集团"), is pleased to announce that its subsidiary, Clearbridge Medical Group Pte. Ltd. ("CBMG"), has entered into a purchase contract with, among others, China National Biotec Group Company Limited (中国生物技术股份有限公司) ("CNBG") and Beijing Institute of Biological Product Co., Ltd. (北京生物制品研究所有限责任公司) ("BIBP"), a subsidiary of CNBG, to purchase the SARS-CoV-2 Vaccine (Vero Cell), Inactivated or COVID-19 Vaccine (Vero Cell), Inactivated, also known as COVID-19 Vaccine BIBP (the "Sinopharm COVID-19 Vaccine") for use in Singapore.

Based on a World Health Organization ("WHO") COVID-19 Vaccine – Explainer Document¹ dated 24 May 2021 (the "WHO Explainer"), the Sinopharm COVID-19 Vaccine is a form of vaccine categorised as "inactivated vaccines" which is reported to stimulate the body's immune system without risk of causing disease. Once inactivated viruses are presented to the body's immune system, they stimulate the production of antibodies, which prepares the body to respond to future live SARS-CoV-2 infections. In addition, the WHO Explainer had also cited a result of a large multi-country phase 3 trial which has shown that two doses administered at an interval of 21 days had the efficacy of 79% against symptomatic SARS-CoV-2 infection 14 days or more after the second dose. The Sinopharm COVID-19 Vaccine does not guarantee full immunity against COVID-19.

The Sinopharm COVID-19 Vaccine has been authorised for use in several countries including the People's Republic of China, the United Arab Emirates, Malaysia, Thailand and Indonesia. It has also been listed by the WHO for emergency use.

Medic Surgical Private Limited ("Medic Surgical"), a subsidiary of the Group, which operates Medic Surgical & Laser Clinic has been granted approval under the Health Sciences Authority of Singapore's ("HSA") Special Access Route ("SAR") scheme to import and supply the Sinopharm COVID-19 Vaccine in Singapore (the "SAR Approval").

¹ Source: <https://www.who.int/publications/m/item/sinopharm-vero-cell---inactivated-covid-19-vaccine>



The Group is currently exploring opportunities in other markets for the Sinopharm COVID-19 Vaccine.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said, “Vaccines are a very crucial tool in our fight against COVID-19 and we are excited to procure Sinopharm COVID-19 vaccine for use in Singapore.”

– END –

This press release is to be read in conjunction with Clearbridge’s exchange filings on 9 August 2021, which can be downloaded via www.sgx.com.

Issued on behalf of Clearbridge Health Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

About Clearbridge Health Limited

(Bloomberg Code: CBH:SP / Reuters Code: CLEA.SI / SGX Code: 1H3)

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine and healthcare solutions in Asia. Its business comprises healthcare systems, medical clinics/centres and the distribution platform of healthcare solutions and technologies from its global clinical partners and strategic medical technology investments.

Through the delivery of precision medicine and healthcare solutions in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients. It is executing the above strategies by way of primary healthcare and healthcare systems that reside in nexus of high demand.

For more information, please visit us at www.clearbridgehealth.com.

This press release has been prepared by the Company and has been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “Sponsor”), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalyst. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.